Table 3.

Univariate survival analysis of 245 breast cancer patients treated with surgery followed by anthracycline-based adjuvant chemotherapy

Variablen (%)EventsDFS (mean ± SD)P, log-rank testEventsOS (mean ± SD)P, log-rank test
Size<0.005>0.1
    T1127 (52.3)25111.7 ± 4.3320115.4 ± 4.09
    T2100 (41.1)3199.2 ± 5.4118114.9 ± 4.35
    T316 (6.6)954.9 ± 7.45476.4 ± 7.47
Grade<0.005<0.1
    123 (9.6)1116.8 ± 3.941117 ± 3.64
    269 (28.7)12116.4 ± 4.988121 ± 4.93
    3148 (61.7)5095.9 ± 4.5233109 ± 4.00
Lymph node metastasis<0.0001<0.0005
    No83 (35.0)10122.2 ± 3.965129 ± 2.60
    Yes154 (65.0)5493.5 ± 4.6137105 ± 4.32
Lymphovascular invasion>0.1>0.1
    No82 (33.7)19109.9 ± 5.1811121 ± 4.15
    Yes161 (66.3)4694.9 ± 4.0431104 ± 3.73
ER<0.050.0001
    Negative48 (20.1)1981.2 ± 6.941786.8 ± 6.53
    Positive191 (79.9)44107.9 ± 3.7324119.2 ± 3.17
PgR>0.1<0.0005
    Negative64 (26.8)2189.3 ± 6.252092.8 ± 5.84
    Positive175 (73.2)42106.9 ± 3.9221119.7 ± 3.33
HER2>0.1>0.1
    Negative200 (84.7)52104.3 ± 3.7532115 ± 3.43
    Positive36 (15.3)1192.9 ± 7.719102 ± 7.28
EGFR>0.1<0.1
    Negative222 (91.0)57105 ± 3.5535115.5 ± 3.18
    Positive22 (9.0)886 ± 9.62792.3 ± 8.79
Ck-14>0.1<0.05
    Negative221 (90.9)57104.2 ± 3.6534116.0 ± 3.13
    Positive22 (9.1)884.5 ± 10.13886.6 ± 9.47
Ck-5/6<0.1<0.01
    Negative210 (89.4)53105.4 ± 3.6332116.2 ± 3.19
    Positive25 (10.6)1080.4 ± 9.81986.8 ± 8.95
Ck-17<0.05<0.0001
    Negative213 (88.4)51106.5 ± 3.6028118.5 ± 3.06
    Positive28 (11.6)1277.2 ± 9.411280.3 ± 8.72
Basal markers<0.05<0.001
    Negative204 (84.0)49106.8 ± 3.6728117.7 ± 3.19
    Positive39 (16.0)1679.4 ± 7.851487.1 ± 7.13
Nielsen groups>0.1<0.005
    Basal30 (13.0)1281.3 ± 8.741187.2 ± 8.01
    Luminal164 (71.3)1192.9 ± 7.7119102.2 ± 7.28
    HER236 (15.7)37107.9 ± 4.139119.1 ± 3.68
p53<0.05<0.001
    Negative158 (70.2)37107.8 ± 3.9918120 ± 3.52
    Positive67 (29.8)2394.9 ± 6.9320103 ± 6.06
MIB-1 (%)<0.05<0.005
    <1096 (42.5)18112.2 ± 5.0411122.4 ± 3.66
    10-3097 (42.9)29100.8 ± 5.4716111.4 ± 5.48
    >3033 (14.6)1576.4 ± 8.381388.8 ± 8.44
Cyclin D1<0.1<0.05
    Negative/Weak26 (11.7)1170.8 ± 7.812681.1 ± 7.64
    Moderate46 (20.6)1286.8 ± 6.0446106.2 ± 6.29
    Strong151 (67.7)36107.7 ± 4.08151118.2 ± 3.51
CCND1>0.1>0.1
    Nonamplified211 (87.6)56103.6 ± 3.6737114 ± 3.25
    Amplified30 (12.4)994.8 ± 8.175107 ± 6.81
CAV1<0.05<0.05
    Negative221 (90.6)55160 ± 3.4834116.3 ± 3.08
    Positive23 (9.4)1071.4 ± 8.17882.2 ± 7.91
  • NOTE: Nielsen groups are immunophenotypic groups.